Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Angiogenesis therapy successful for peripheral arterial disease

14.10.2004


Duke University Medical Center researchers have shown that they can stimulate the body to produce its own naturally occurring growth factors to promote blood vessel growth into tissue damaged by peripheral arterial obstructive disease (PAOD). They said their finding could offer a new approach to treating the disease, which rivals coronary artery disease in its prevalence and health impact.



The researchers injected into rabbits with a version of PAOD a gene-carrying molecule, called a plasmid, which carried a gene that is the blueprint for a protein known as the "zinc-finger-activating" (ZFP) transcription factor. Transcription factors are proteins that switch on other genes.

In the rabbits, the gene produced ZFP transcription factor that successfully activated a key blood-vessel-growth gene, called VEGF, whose protein product triggers blood vessel growth, found the researchers.


Importantly, the researchers demonstrated that this plasmid stimulated the production of three different forms of VEGF, much as the body would on its own. The researchers said they believe that the latest finding is an important advance in the field of therapeutic angiogenesis -- the process of blood vessel growth -- because past studies of VEGF in humans have only involved one form of VEGF and have seen only limited success..

In addition to stimulating new vessel growth and improving perfusion in the damaged leg tissue, the treatment also appeared to prevent the programmed cell death, known as apoptosis, of muscle cells starved of blood supply but not yet dead, the researchers reported. The results of the Duke study, led by cardiologist Brian Annex, M.D., are scheduled to be published in the Oct. 19, 2004, issue of the journal Circulation, and are available on-line at http://circ.ahajournals.org/.

"Peripheral arterial obstructive disease, which has a national incidence approaching that of coronary artery disease, is a major health care issue for which there are few effective remedies," Annex said. "This new agent may provide a novel and effective approach to treating a disease that can be just as debilitating as coronary artery disease."

The National Institutes of Health (NIH) has just begun a clinical trial using the plasmid, and Duke will also initiate a similar clinical trial in the coming months.

It is estimated between 8 to 12 million Americans suffer from PAOD. In mild cases, known as intermittent claudication, patients feel muscle pain upon exertion. More severe cases, known as critical limb ischemia, can lead to gangrene or tissue death, often necessitating amputation of the effected limb. While there are drugs and invasive procedures for the disorder, none are particularly effective, the researchers said.

VEGF, because of its ability to stimulate new blood vessel growth, is a naturally occurring substance that has intrigued scientists for years, said the Duke researchers. Cancer specialists, for example, are looking at ways of blocking VEGF-induced blood supply to tumors, while cardiologists are attempting to harness its properties to replenish blood flow to starving tissues throughout the body.

Earlier studies in mice had shown that the ZFP-carrying plasmid could induce VEGF production and stimulate angiogenesis, but the Duke study was the first one to show efficacy in an ischemic model. "While we’ve have limited success using VEGF for patients with peripheral arterial disease, we feel that new approach will have a better chance of succeeding," Annex said. "In previous studies, only one form of the VEGF protein was used. This new approach appears to give the body control over the production of the amounts and types of VEGF that it needs."

For their experiments, the researchers induced limb ischemia in the hind legs of rabbits. Ten days later, they injected the plasmid into the effected legs. At regular intervals during the next 32 days, the researchers measured the effects of treatment and found that when compared to the non-treated legs, the treated legs had an increase in capillary density, a positive increase in cellular proliferation and improved tissue perfusion.

Additionally, the researchers found significant increases in the circulating levels of three forms of VEGF – VEGF-121, VEGF-165, and VEGF-189. "Each form varies in its affinity for binding to tissue and may different effects," Annex explained. "VEGF-121, for example, is fairly soluable, so when you inject it into the leg, it travels throughout the body. This is the form used in past human trials.

"VEGF-189, on the other hand, does not easily go into circulation, so it stays where you put it," Annex continued. "VEGF-165 is somewhere in the middle. However, what’s most important is that we saw elevated levels of all three, which would indicate that the body was creating those forms in the amounts it needed."

The researchers also found that the treatment appeared to protect damaged cells from undergoing the process of apoptosis. "The results of these preclinical studies demonstrate for the first time that stimulating innate VEGF gene expression leads to the creation of multiple forms of VEGF that appear to provide therapeutic angiogenesis," Annex said.

Richard Merritt | EurekAlert!
Further information:
http://www.duke.edu

More articles from Health and Medicine:

nachricht Electrical 'switch' in brain's capillary network monitors activity and controls blood flow
27.03.2017 | Larner College of Medicine at the University of Vermont

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Northern oceans pumped CO2 into the atmosphere

27.03.2017 | Earth Sciences

Fingerprint' technique spots frog populations at risk from pollution

27.03.2017 | Life Sciences

Big data approach to predict protein structure

27.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>